文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

供者类型与预处理强度对镰状细胞病异基因移植结局的影响

Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
PubMed 文献 · Lancet Haematol · 2019-09-05

该回顾性多中心队列研究纳入2008-2017年美国90个中心910例接受异基因造血干细胞移植的镰状细胞病患者,比较供者类型与预处理强度对无事件生存的影响。结果显示,年龄≥13岁及接受单倍体相合、相合无关或不相合无关供者移植者无事件生存较差;非同胞供者间无显著差异,减低强度预处理方案结局劣于非清髓方案。

要点

  • 非同胞供者移植无事件生存均劣于HLA相合同胞供者。
  • 非同胞供者间无事件生存无显著差异。

核心结论

  • 年龄≤12岁及有HLA相合同胞供者的镰状细胞病患者异基因移植无事件生存更优。
  • 无相合同胞供者时,现有数据不支持优先选择某一种替代供者类型。

研究设计与样本

  • 回顾性多中心队列研究,收集美国90个中心2008年1月15日至2017年12月28日间移植数据。
  • 纳入年龄<50岁、基因确诊Hb SS或Hb Sβ且接受异基因造血干细胞移植的患者。
  • 996例中910例(91%)纳入分析,中位随访时间因供者类型而异。

临床怎么用

  • 对镰状细胞病患者,应尽早考虑移植,年龄≤12岁者无事件生存更优。
  • 优先选择HLA相合同胞供者进行移植。
  • 无相合同胞供者时,替代供者类型选择需个体化,现有数据未显示某一种更优。
  • 预处理方案选择需权衡,减低强度方案的无事件生存劣于非清髓方案。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 中位随访时间较短且各供者类型组间不一致。
  • 未报告全部潜在混杂因素的详细分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Donors other than matched siblings and low-intensity conditioning regimens are increasingly used in haematopoietic stem cell transplantation. We aimed to compare the relative risk of donor type and conditioning regimen intensity on the transplantation outcomes of in patients with sickle cell disease. METHODS: For this retrospective cohort study, we collected data from 90 US centres reported to the Center for International Blood and Marrow Transplant Research. Eligible patients were younger than 50 years, had genetically confirmed sickle cell disease (Hb SS) or sickle beta thalassemia (Hb Sβ), and underwent allogeneic haematopoietic cell transplantation between Jan 15, 2008, and Dec 28, 2017. We considered transplants from donor-recipient pairs matched at the allele-level (HLA-A, HLA-B, HLA-C, and HLA-DRB1), including HLA-matched sibling donors, haploidentical related donors, matched unrelated donors, or mismatched unrelated donors. The main outcome was event-free survival. The effect of donor type, conditioning regimen intensity (myeloablative, non-myeloablative, and reduced-intensity regimens), age (≤12 or 13-49 years), sex, performance score, comorbidity index, recipient cytomegalovirus serostatus, graft type (bone marrow, peripheral blood, or umbilical cord blood), and transplantation period (2008-12 and 2013-17) on outcomes was studied using Cox regression models. FINDINGS: Of 996 patients with sickle cell disease and who underwent transplantation in 2008-17, 910 (91%) were included (558 [61%] patients had HLA-matched sibling donors, 137 [15%] haploidentical related donors, 111 [12%] matched unrelated donors, and 104 [11%] mismatched unrelated donors). The median follow-up was 36 months (IQR 18-60) after transplantation from HLA-matched siblings, 25 months (12-48) after transplantation from haploidentical related donors, 37 months (23-60) after transplantation from HLA-matched unrelated donors, and 47 months (24-72) after transplantation from mismatched unrelated donors. Event-free survival was worse in recipients aged 13 years or older than in those younger than 13 years (hazard ratio 1·74, 95% CI 1·24-2·45; p=0·0014) and in those who received a transplant from haploidentical related donors (5·30, 3·17-8·86; p<0·0001), matched unrelated donors (3·71, 2·39-5·75; p<0·0001), and mismatched unrelated donors (4·34, 2·58-7·32; p<0·0001) than in patients who received a transplant from matched siblings. There was no significant difference in event-free survival between recipients of transplants from non-sibling donors: haploidentical related donors (1·43, 0·81-2·50; p=0·21) or mismatched unrelated donors (1·17, 0·67-2·05; p=0·58) versus HLA-matched unrelated donors, or mismatched unrelated donors versus haploidentical related donors (1·22, 0·65-2·27; p=0·98). Event-free survival was also worse in patients conditioned with reduced-intensity regimens (1·97, 1·15-3·36; p=0·013) than in those conditioned with non-myeloablative regimens, but did not differ between those who received myeloablative compared with non-myeloablative regimens (1·57, 0·95-2·61; p=0·079). Interpretation Our data suggest that event-free survival is improved in patients with sickle cell disease who receive an allogenic transplantation at age 12 years or younger and those with an HLA-matched sibling donor. For patients without a matched sibling available for transplantation, our data do not favour one alternative donor type over another in this setting. FUNDING: National Institutes of Health and US Health Services Research Administration, Department of Health and Human Services.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019. PMID: 31495699. doi:10.1016/S2352-3026(19)30154-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。